ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0112

Description of Risk Factors at Baseline and Need of Bone Agent According to Hadji Recommendations in Patients Taking Aromatase Inhibitors as Breast Cancer Therapy

David Montero-Seisdedos1, Oihane Ibarguengoitia-Barrena2, Lucía Vega-Álvarez2, Carmen Lucía García Gomez2, Itziar Calvo-Zorrilla3, Juan M. Blanco-Madrigal2, Maria Esther Ruiz-Lucea2, María Luz García-Vivar2, Eva Galindez-Agirregoikoa2, Ana R. Inchaurbe-Pellejero2, Olaia Fernandez-Berrizbeitia2, Clara E. Perez-Velasquez2, Eduardo Cuende-Quintana4, Amaia Bilbao-González3 and Iñaki Torre-Salaberri3, 1Basurto University Hospital, Bilbao, Pais Vasco, Spain, 2Basurto University Hospital, Bilbao, Spain, 3University Hospital of Basurto, Bilbao, Pais Vasco, Spain, 4Basurto University Hospital, Madrid, Spain

Meeting: ACR Convergence 2020

Keywords: Bone density, osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Osteoporosis & Metabolic Bone Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: A well-known adverse effect of aromatase inhibitors (AI) in the bone is the loss of mineral density with the consequent increased risk of fracture (fx).

A widely used algorithm for the management of bone agent treatment in patients taking AI is that of Hadji from 2011. Depending on the risk factors and densitometric values, patients would or would not be subsidiaries of receiving such treatment.

Methods: Retrospective cross-sectional study of 200 patients collected in the period between 2014 and 2019 on the monographic consultation of osteoporosis, referred by Medical Oncology to assess the risk of fracture at the start of AI treatment after being diagnosed with breast cancer. BMD and clinical risk factors for fractures are included, based on the 2011 Hadji algorithm, what percentage of patients required treatment with bone agents during follow-up.

Results: The average age of our sample is 64.8 years with a SD of 9.5 and a median of 64.5 (Q1 58
and Q3 72). Regarding the treatment, 56 patients (28%) took Anastrozole, 122 (61%) Letrozole and 22 (11%) Exemestane. The risk factors are: 28 patients (14%) were active smokers and 35 (17.5%) ex-smokers; 11 (5.5%) recognized daily alcohol intake at significant doses. 42 women (21%) had previous fx, of which 15 (35.71%) were on the wrist, 8 (19.05%) vertebral, 2 (4.76%) on the shoulder and 1 (2.38%) on the hip. 44 women (22%) recognized habitual falls and 15 (7.5%) had familiar history of hip fx. There were no patients on chronic steroid treatment and 9 (4.5%) had osteoporosis secondary to a chronic disease. The DXA at the baseline visit showed OP in 64 patients (32%), osteopenia in 108 (54%) and normality in the other 28 (14%). In the blood tests, all women except 1 had normal phospho-calcium levels. Regarding VitD, 13 patients (6.67%) had values < 10 ng/mL, 50 (25.64%) from 10 to 20, 68 (34.87%) from 20 to 30, and the remaining 64 (32.82%) over 30 ng/mL. PTHi levels were high in 15 women (7.69%) and the CTX was elevated in 34 (17.53%). Monitoring data is collected with the following interest: 12 patients (6%) suffer a new fx during AI treatment, 58% vertebral, 25% wrist, and 16% in other locations. 121 women in our sample (60.5%) received treatment for OP according to Hadji's protocol, 92 (76.03%) of them alendronate, 7 (5.79%) risedronate, 18 (14.88%) denosumab, and the remaining 4 (3.3% ) zoledronate and ibandronate in equal proportion (1.65%).

Conclusion: 60.5% of the patients in our series required a bone agent based on the Hadji combining risk factors and BMD values. Highlight that only 30% of patients presented osteoporosis values in DXA at the initial assessment and that 21% had previous fractures, the most on the wrist. We consider the systematic assessment of the risk of fracture presented by patients with breast cancer who begin treatment with AI, assessing the need to prescribe bone agents using an algorithm as practical as that of Hadji.


Disclosure: D. Montero-Seisdedos, None; O. Ibarguengoitia-Barrena, None; L. Vega-Álvarez, None; C. García Gomez, None; I. Calvo-Zorrilla, None; J. Blanco-Madrigal, None; M. Ruiz-Lucea, None; M. García-Vivar, None; E. Galindez-Agirregoikoa, None; A. Inchaurbe-Pellejero, None; O. Fernandez-Berrizbeitia, None; C. Perez-Velasquez, None; E. Cuende-Quintana, None; A. Bilbao-González, None; I. Torre-Salaberri, None.

To cite this abstract in AMA style:

Montero-Seisdedos D, Ibarguengoitia-Barrena O, Vega-Álvarez L, García Gomez C, Calvo-Zorrilla I, Blanco-Madrigal J, Ruiz-Lucea M, García-Vivar M, Galindez-Agirregoikoa E, Inchaurbe-Pellejero A, Fernandez-Berrizbeitia O, Perez-Velasquez C, Cuende-Quintana E, Bilbao-González A, Torre-Salaberri I. Description of Risk Factors at Baseline and Need of Bone Agent According to Hadji Recommendations in Patients Taking Aromatase Inhibitors as Breast Cancer Therapy [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/description-of-risk-factors-at-baseline-and-need-of-bone-agent-according-to-hadji-recommendations-in-patients-taking-aromatase-inhibitors-as-breast-cancer-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/description-of-risk-factors-at-baseline-and-need-of-bone-agent-according-to-hadji-recommendations-in-patients-taking-aromatase-inhibitors-as-breast-cancer-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology